Septal Thickness Does Not Impact Outcome After Hypertrophic Obstructive Cardiomyopathy Surgery (Septal Myectomy and Subvalvular Mitral Apparatus Remodeling): A 15-Years of Experience.
extensive myectomy
hypertrophic obstructive cardiomyopathy
mitral approach
mitral valve repair
systolic anterior motion
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
01
2022
accepted:
16
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
The aim of this study was to assess the impact of septal thickness on long-term outcomes of surgical treatment for hypertrophic obstructive cardiomyopathy (HOCM) and correction of mitral subvalvular anomalies. Sixty-six consecutive patients (58 ± 12 years, 56% female) undergoing extended septal myectomy and subvalvular mitral apparatus remodeling from 2007 to 2021 were retrospectively reviewed. Patients were divided into 2 groups according to septal thickness: moderate [< 18 mm, 29 patients (44%)] and severe [≥ 18 mm, 37 patients (56%)]. End points included survival, symptom improvement, reduction of left ventricle outflow tract (LVOT) gradient, resolution of mitral regurgitation (MR), and reoperation. The mean interventricular septal thickness was 19 ± 3 mm, 15.8 ± 0.8 mm in patients with moderate and 21.4 ± 3.2 mm in those with severe hypertrophy. Preoperative data, intraoperative variables, postoperative complication rates, pre-discharge echocardiographic and clinical parameters did not differ between the two study groups [except for procedures involving the posterior mitral leaflet ( Regardless of septal thickness, subvalvular apparatus remodeling with concomitant septal myectomy can provide satisfactory long-term outcomes in terms of symptom improvement, LVOT obstruction relief, and MR resolution (without mitral valve replacement in most cases) in patients with HOCM.
Sections du résumé
Background
UNASSIGNED
The aim of this study was to assess the impact of septal thickness on long-term outcomes of surgical treatment for hypertrophic obstructive cardiomyopathy (HOCM) and correction of mitral subvalvular anomalies.
Methods
UNASSIGNED
Sixty-six consecutive patients (58 ± 12 years, 56% female) undergoing extended septal myectomy and subvalvular mitral apparatus remodeling from 2007 to 2021 were retrospectively reviewed. Patients were divided into 2 groups according to septal thickness: moderate [< 18 mm, 29 patients (44%)] and severe [≥ 18 mm, 37 patients (56%)]. End points included survival, symptom improvement, reduction of left ventricle outflow tract (LVOT) gradient, resolution of mitral regurgitation (MR), and reoperation.
Results
UNASSIGNED
The mean interventricular septal thickness was 19 ± 3 mm, 15.8 ± 0.8 mm in patients with moderate and 21.4 ± 3.2 mm in those with severe hypertrophy. Preoperative data, intraoperative variables, postoperative complication rates, pre-discharge echocardiographic and clinical parameters did not differ between the two study groups [except for procedures involving the posterior mitral leaflet (
Conclusions
UNASSIGNED
Regardless of septal thickness, subvalvular apparatus remodeling with concomitant septal myectomy can provide satisfactory long-term outcomes in terms of symptom improvement, LVOT obstruction relief, and MR resolution (without mitral valve replacement in most cases) in patients with HOCM.
Identifiants
pubmed: 35783828
doi: 10.3389/fcvm.2022.853582
pmc: PMC9242021
doi:
Types de publication
Journal Article
Langues
eng
Pagination
853582Informations de copyright
Copyright © 2022 Raffa, Franca, Lachina, Palmeri, Kowalewski, Lebowitz, Ricasoli, Greco, Sciacca, Turrisi, Morsolini, Stringi, Mattiucci and Pilato.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Coll Cardiol. 2015 Oct 13;66(15):1687-96
pubmed: 26449139
Circulation. 1988 Sep;78(3):487-95
pubmed: 3409494
Ann Thorac Surg. 2019 Feb;107(2):460-466
pubmed: 30326232
Eur J Cardiothorac Surg. 2016 Jul;50(1):61-5
pubmed: 26792931
Interact Cardiovasc Thorac Surg. 2019 Mar 1;28(3):465-472
pubmed: 30184144
Ann Thorac Surg. 2019 Sep;108(3):964
pubmed: 30836098
Interact Cardiovasc Thorac Surg. 2017 Sep 1;25(3):356-362
pubmed: 28575282
Ann Surg. 1961 Aug;154:181-9
pubmed: 13772904
Ann Thorac Surg. 2008 Jan;85(1):127-33
pubmed: 18154797
Am J Cardiol. 2015 Mar 1;115(5):670-5
pubmed: 25591899
J Am Soc Echocardiogr. 2016 Jul;29(7):622-39
pubmed: 27146120
Heart Lung Circ. 2021 Feb;30(2):e45-e46
pubmed: 32782199
J Am Coll Cardiol. 2015 Sep 15;66(11):1307-1308
pubmed: 26361164
Eur J Cardiothorac Surg. 2017 Oct 1;52(4):616-664
pubmed: 29156023
Eur J Cardiothorac Surg. 2021 Jul 30;60(2):244-251
pubmed: 33624799
Eur J Cardiothorac Surg. 2018 Mar 1;53(3):582-589
pubmed: 29182736
Heart Lung Circ. 2019 Mar;28(3):477-485
pubmed: 29602755
J Am Coll Cardiol. 2016 Apr 19;67(15):1846-1858
pubmed: 27081025
Eur Heart J. 2012 Aug;33(16):2080-7
pubmed: 22522842
Circ Cardiovasc Imaging. 2015 Jul;8(7):e003132
pubmed: 26082555
J Cardiol. 2022 Jan;79(1):42-49
pubmed: 34551867
J Thorac Cardiovasc Surg. 2010 Aug;140(2):317-24
pubmed: 20038476
J Am Coll Cardiol. 2005 Aug 2;46(3):470-6
pubmed: 16053960
J Am Coll Cardiol. 2020 Dec 22;76(25):e159-e240
pubmed: 33229116
Ann Thorac Surg. 2020 Sep;110(3):783-789
pubmed: 32389564